Summary An established chemical faecal occult blood test (Haemoccult prepared without rehydration) has been compared with a new immunological test (Hemeselect) in patients referred for investigation of lower gastro-intestinal symptoms.
Faecal occult blood tests are potentially useful in the preliminary assessment of subjects with symptoms of colorectal disease (Leicester et al., 1983) and also for mass population screening for asymptomatic colorectal neoplasia. The test commonly used for screening, Haemoccult (Rohm Pharma) has an estimated sensitivity in the range 50-65% for asymptomatic cancers (Kewenter et al., 1988; Kronborg et al., 1989; Hardcastle et al., 1989) and has been noted to be particularly insensitive for rectal and caecal cancers, missing over 50% of malignancies at these sites (Kronborg et al., 1989; Hardcastle et al., 1989) . In contrast over 70% of sigmoid cancers are detected. One of the proposed mechanisms for this discrepancy is that Haemoccult, which is essentially a test for the Haematin moiety of Haemoglobin, relies on an optimum degree of Haemoglobin degradation which is most commonly achieved by blood loss from sigmoid cancers.
Immunological tests, not dependent on Haematin, should reliably detect bleeding from rectal cancers, although they may also be affected by excessive degradation of blood from caecal cancers. Hemeselect (Smith-Kline Diagnostics) utilises fixed chicken erythrocytes that have coated with an antihuman haemoglobin antibody. Faecal matter is smeared onto filter paper by the patients. Small discs of the paper are then used to obtain a dilute faecal solution to which the coated chicken erythrocytes are added, erythrocyte agglutination occurs in the presence of haemoglobin in the faecal solution. The sensitivity of both tests was independent of tumour stage (Table II) .
A total of 26 adenomatous polyps were diagnosed in 21 patients (Table III) 
Discussion
Faecal occult blood testing of patients with symptoms of colorectal disease remains a controversial, but widespread practice. We believe that patients with such symptoms should undergo appropriate endoscopic or radiological investigation, however other authors have emphasised the usefulness of preliminary faecal occult blood testing, especially in identifying subjects worthy of urgent investigation (Leicester et al., 1983) .
In this respect Haemoccult, interpreted without rehydration, would appear to be of limited value, detecting only 58% of symptomatic cancers. Previous series have reported a sensitivity of 45-81% for symptomatic cancers (Barrison et al., 1985; Aldercreutz et al., 1984) ; an earlier report from this department demonstrated a sensitivity of 72% when Haemoccult was performed over 3 days (Farrands & Hardcastle, 1983) , the lower overall sensitivity seen in the present study may reflect the large number of rectal tumours in the cohort of patients with carcinoma. One method of improving Haemoccult sensitivity which has been explored is the rehydration of the test cards before the application of hydrogen peroxide, however this also significantly reduces specificity for neoplasia (Mandel et al., 1989; Kewenter et al., 1988) and in the present study all Haemoccult tests were interpreted without rehydration.
The excellent sensitivity of Hemeselect makes this a more suitable test for use in symptomatic subjects, our results suggest that approximately a third of patients with symptoms compatible with colorectal neoplasia could be given priority outpatient assessment and investigation and that 98% of those with a malignancy would be identified by the F.O.B. test. St John et al. (1990) have described a similar sensitivity (95%) for symptomatic cancers, although in their series 89% of patients also had a positive Haemoccult test.
It seems probable that the main reason for the enhanced sensitivity of Hemeselect for neoplasia is its ability to detect small quantities of faecal blood (Yoshida et al., 1986) , however it appears that lack of haemoglobin degradation may also adversely affect the performance of Haemoccult as the greatest difference in sensitivity between the tests was for rectal cancers.
The potential use of Hemeselect as a highly sensitive screening test for asymptomatic neoplasia is also raised by this study. Our results suggest that it would also be more sensitive than Haemoccult for asymptomatic neoplasia, but that this improvement would be achieved at the expense of specificity. The specificity of 84.1% for colorectal neoplasia achieved in the present study would be inadequate for a screening test although an improvement in specificity would be expected if the tests were used in asymptomatic individuals where blood loss from benign conditions would have less influence. In accordance with the United Kingdom Coordinating Committee for Cancer Research (UKCCCR) recommendations regarding the evaluation of F.O.B. tests a preliminary study to assess the overall positivity rate in asymptomatic subjects is now being undertaken and will be followed by a larger screening study to determine the comparative yield of neoplasia and specificity of Haemoccult and Hemeselect in asymptomatic subjects.
